RRP9 Antibody

What is RRP9 and what cellular functions does it perform?

RRP9 (also known as U3-55K or RNU3IP2) is a component of the nucleolar small nuclear ribonucleoprotein particle (snoRNP) that participates in the processing and modification of pre-ribosomal RNA (pre-rRNA) . It is part of the small subunit (SSU) processome, which is the first precursor of the small eukaryotic ribosomal subunit . During SSU processome assembly in the nucleolus, RRP9 works with other ribosome biogenesis factors to generate RNA folding, modifications, rearrangements, and cleavage . RRP9 is specifically required for cleavage at sites A0, A1, and A2 in pre-rRNA processing .

What types of RRP9 antibodies are commercially available and what applications are they validated for?

Currently, commercially available RRP9 antibodies include rabbit polyclonal antibodies that have been validated for various applications:

The ab168845 antibody has been raised against a synthetic peptide within human RRP9 amino acids 150-250 , while the 10311-1-AP antibody was generated using RRP9 fusion protein Ag0319 . These antibodies show specificity for RRP9 protein with an observed molecular weight of 52-55 kDa, which is consistent with its calculated molecular weight of 52 kDa .

How should RRP9 antibodies be stored and handled to maintain optimal performance?

RRP9 antibodies should be stored at -20°C, where they remain stable for one year after shipment . Small aliquots (such as 20μL) containing 0.1% BSA can be stored without further aliquoting . The storage buffer typically consists of PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 . When working with these antibodies, avoid repeated freeze-thaw cycles to maintain antibody integrity and performance.

What are the recommended protocols for using RRP9 antibodies in Western blot analysis?

For Western blot applications using RRP9 antibodies, the following protocol is recommended:

• Sample preparation: Extract total protein from cells or tissues using appropriate lysis buffers

• Protein quantification: Determine protein concentration using Bradford or BCA assay

• SDS-PAGE: Load 20-30μg of protein per lane

• Transfer: Transfer proteins to PVDF or nitrocellulose membrane

• Blocking: Block membrane with 5% non-fat milk in TBST for 1 hour at room temperature

• Primary antibody incubation: Dilute RRP9 antibody 1:500-1:1000 in blocking buffer and incubate overnight at 4°C

• Washing: Wash membrane with TBST (3 times, 5 minutes each)

• Secondary antibody incubation: Incubate with HRP-conjugated secondary antibody for 1 hour at room temperature

• Detection: Visualize using ECL substrate and imaging system

The RRP9 protein should be detected at approximately 52-55 kDa . Positive controls include HepG2 cells and HeLa cells, which have been confirmed to express detectable levels of RRP9 .

How can I design experiments to study RRP9 protein interactions and its role in protein complexes?

To study RRP9 protein interactions and its role in protein complexes, consider these methodological approaches:

• Co-immunoprecipitation (Co-IP):

  • Use RRP9 antibodies to pull down RRP9 and its interacting partners

  • RRP9 has been shown to interact with proteins like JUN and IGF2BP1

  • For example, researchers have demonstrated that RRP9 interacts with the JUN protein through Co-IP assays

• Reciprocal Co-IP validation:

  • Perform reverse Co-IP using antibodies against suspected interacting partners

  • Confirm interactions by western blot analysis using specific antibodies

• Domain mapping:

  • Create truncated versions of RRP9 to identify interaction domains

  • For instance, the WD40 domain (aa 145-475) of RRP9 has been shown to interact with Smurf1

• Protein stability assays:

  • Examine how RRP9 affects the stability of interacting proteins

  • Use cycloheximide chase assays to track protein degradation rates

  • RRP9 has been shown to affect JUN protein stability by regulating its ubiquitination

• Ubiquitination assays:

  • Investigate how RRP9 affects the ubiquitination status of interacting proteins

  • For example, RRP9 deletion was found to increase JUN ubiquitination via MDM2

• Immunofluorescence co-localization:

  • Visualize the subcellular localization of RRP9 and its binding partners

  • This technique has been used to demonstrate the relationship between RRP9 and IGF2BP1

What cell lines are most appropriate for studying RRP9 expression and function?

Based on the available research, the following cell lines have been used successfully for studying RRP9 expression and function:

MDA-MB-231 and BT549 cell lines show particularly high expression of RRP9 compared to the human mammary epithelial line MCF-10A, making them excellent models for RRP9 knockdown studies . For pancreatic cancer research, various pancreatic cancer cell lines have also been utilized to study RRP9's role in gemcitabine resistance .

What is the relationship between RRP9 expression and cancer progression?

Research has revealed significant correlations between RRP9 expression and cancer progression:

These findings indicate that RRP9 may serve as a prognostic marker and potential therapeutic target in multiple cancer types.

How does RRP9 influence cellular signaling pathways in cancer?

RRP9 has been shown to influence several key signaling pathways in cancer:

• AKT Signaling Pathway:

  • RRP9 activates the AKT signaling pathway in breast cancer and pancreatic cancer

  • RRP9 knockdown decreases phosphorylation of AKT (p-AKT)

  • In BT549 cells, RRP9 depletion decreased protein levels of p-AKT, CCND1, and CDK1

  • Treatment with the AKT activator SC79 can reverse the effects of RRP9 knockdown on cell apoptosis

• JUN-Mediated Pathways:

  • RRP9 interacts with the JUN protein and regulates its stability

  • RRP9 deletion enhances JUN ubiquitination, leading to JUN degradation via MDM2

  • JUN overexpression can counteract the effects of RRP9 knockdown

• IGF2BP1 Interaction:

  • In pancreatic cancer, RRP9 interacts with the DNA binding region of IGF2BP1

  • This interaction activates the AKT signaling pathway, promoting cancer progression and inducing gemcitabine resistance

These molecular mechanisms suggest that RRP9 promotes cancer progression through multiple interconnected signaling pathways, with the AKT pathway appearing to be central to its oncogenic function.

What phenotypic changes occur following RRP9 knockdown in cancer cells?

RRP9 knockdown induces several significant phenotypic changes in cancer cells:

• Cell Proliferation:

  • Silencing RRP9 significantly inhibits cell proliferation, particularly in MDA-MB-231 and BT549 breast cancer cells

  • RRP9 knockdown reduces colony formation ability in these cell lines

• Cell Cycle:

  • RRP9 knockdown leads to cell cycle arrest in the G2 phase

  • Compared to control groups, RRP9 knockdown results in fewer cells in G1 phase and more cells in G2 phase

• Apoptosis:

  • RRP9 knockdown significantly increases apoptosis in MDA-MB-231 and BT549 cells

  • Western blot analysis confirms increased expression of apoptosis-related proteins following RRP9 depletion

• Cell Migration:

  • Transwell assays demonstrate that RRP9 silencing reduces the migration capacity of MDA-MB-231 and BT549 cells

• In Vivo Tumor Growth:

  • Xenograft models show that RRP9 knockdown significantly delays tumor growth

  • Tumors from RRP9 knockdown groups show reduced weight and volume

  • RRP9 knockdown reduces the expression of Ki-67 (cell proliferation marker), stem cell markers (CD133, OCT4), and chemotactic cytokines (MIP-1α)

• Chemoresistance:

  • In pancreatic cancer, RRP9 knockdown increases sensitivity to gemcitabine treatment

  • RRP9 overexpression induces gemcitabine resistance through reduction in DNA damage and inhibition of apoptosis

How can I distinguish between direct and indirect effects of RRP9 in signaling pathway studies?

To distinguish between direct and indirect effects of RRP9 in signaling pathway studies:

• Proximity Ligation Assays (PLA):

  • Use PLA to detect and visualize direct protein-protein interactions in situ

  • This method can confirm whether RRP9 directly interacts with components of signaling pathways

• Domain Mutation Studies:

  • Create point mutations in specific domains of RRP9

  • Examine which mutations disrupt specific protein interactions or pathway activations

  • For example, mutations in the WD40 domain (aa 145-475) could confirm its role in specific protein interactions

• Rescue Experiments:

  • Perform knockdown of RRP9 followed by reintroduction of wild-type or mutant RRP9

  • Determine which phenotypes can be rescued by specific RRP9 variants

• Time-Course Studies:

  • Monitor activation of signaling pathways at multiple time points after RRP9 manipulation

  • Early changes (minutes to hours) are more likely to represent direct effects

  • Late changes (days) may represent indirect effects or downstream consequences

• Pharmacological Inhibitors:

  • Use specific inhibitors of suspected pathway components

  • For example, the AKT inhibitor MK-2206 has been used to block RRP9-mediated effects in pancreatic cancer

  • If inhibition of a downstream component blocks RRP9's effects, this suggests a dependent relationship

• Network Analysis:

  • Employ systems biology approaches to map direct and indirect interactions

  • Integrate proteomics, transcriptomics, and functional data to build comprehensive networks

What are the most common technical challenges when using RRP9 antibodies and how can they be addressed?

Researchers often encounter several technical challenges when working with RRP9 antibodies:

• Background Signal and Non-specific Binding:

  • Challenge: High background in Western blots or immunostaining

  • Solutions:

    • Increase blocking time or concentration (5-10% BSA or milk)

    • Reduce primary antibody concentration (titrate from 1:500 to 1:2000)

    • Add 0.1-0.3% Triton X-100 in washing buffer to reduce non-specific binding

    • Include additional washing steps after antibody incubations

• Inconsistent Detection of RRP9:

  • Challenge: Variable detection of RRP9 across experiments

  • Solutions:

    • Ensure consistent protein extraction methods

    • Use positive control samples (e.g., HepG2 or HeLa cells)

    • Standardize lysate preparation (fresh vs. frozen)

    • Verify protein loading with housekeeping controls

• Cross-reactivity with Related Proteins:

  • Challenge: Detecting bands at unexpected molecular weights

  • Solutions:

    • Validate with RRP9 knockdown samples as negative controls

    • Use alternative RRP9 antibodies recognizing different epitopes

    • Perform peptide competition assays to confirm specificity

• Co-immunoprecipitation Efficiency:

  • Challenge: Poor yield in RRP9 immunoprecipitation experiments

  • Solutions:

    • Optimize lysis buffer composition (consider RIPA vs. NP-40 buffers)

    • Adjust antibody-to-bead ratio

    • Increase incubation time (overnight at 4°C)

    • Use gentle washing conditions to preserve weak interactions

• Detection in Fixed Tissues:

  • Challenge: Poor immunohistochemical staining in FFPE tissues

  • Solutions:

    • Optimize antigen retrieval methods (citrate vs. EDTA buffers)

    • Test different fixation times during sample preparation

    • Use amplification systems (e.g., tyramide signal amplification)

• Reproducibility Across Different Lots:

  • Challenge: Variation in antibody performance between lots

  • Solutions:

    • Purchase larger quantities of a single lot for long-term studies

    • Validate each new lot against previous lots using standard samples

    • Maintain detailed records of antibody performance

How can RRP9 research findings be translated into potential therapeutic strategies?

Based on current research, several approaches could translate RRP9 research findings into therapeutic strategies:

• Direct Targeting of RRP9:

  • Development of small molecule inhibitors targeting RRP9's functional domains

  • RNAi-based therapies (siRNA, shRNA) for targeted knockdown of RRP9 in tumors

  • CRISPR-based approaches to disrupt RRP9 gene expression in cancer cells

• Combination Therapies:

  • Target RRP9 in combination with chemotherapy

  • For pancreatic cancer, combining RRP9 inhibition with gemcitabine could overcome resistance

  • In breast cancer, RRP9 inhibition may sensitize tumors to standard therapies

• Targeting RRP9-Dependent Pathways:

  • Using existing AKT pathway inhibitors (such as MK-2206) in RRP9-overexpressing tumors

  • Treatment with a combination of AKT inhibitors and gemcitabine has shown significant inhibition of tumor proliferation in RRP9-overexpressing pancreatic cancer models

• Biomarker Development:

  • Develop RRP9 expression as a prognostic biomarker for patient stratification

  • High RRP9 expression correlates with poor prognosis in breast cancer

  • Could identify patients who would benefit from more aggressive treatment approaches

• Disrupting Protein-Protein Interactions:

  • Design peptide inhibitors or small molecules that disrupt specific interactions

  • The RRP9-JUN interaction could be a potential target in breast cancer

  • The RRP9-IGF2BP1 interaction could be targeted in pancreatic cancer

• Precision Medicine Approaches:

  • Identify patient subgroups with RRP9 overexpression

  • Develop tailored treatment strategies based on RRP9 status and associated pathway activation

  • Integrate RRP9 testing into molecular profiling of tumors

The translational potential of RRP9 research is particularly promising in breast and pancreatic cancers, where RRP9 has been shown to play significant roles in disease progression and treatment resistance.

What are the emerging roles of RRP9 beyond cancer research?

While RRP9 has been extensively studied in cancer contexts, emerging research suggests broader roles:

• Ribosomal Biogenesis and Cellular Homeostasis:

  • RRP9 is a component of the small subunit (SSU) processome involved in pre-rRNA processing

  • Further investigation into how RRP9 regulates normal cellular homeostasis through ribosome biogenesis is warranted

  • Disruptions in this process may contribute to various diseases beyond cancer

• Post-translational Modifications:

  • RRP9 is subject to neddylation, a post-translational modification that attaches ubiquitin-like protein Nedd8 to protein targets

  • The role of neddylated RRP9 in normal cellular processes remains to be fully elucidated

• RNA Metabolism Beyond rRNA Processing:

  • As a U3 snoRNA-binding protein, RRP9 may have broader roles in RNA metabolism

  • Research into whether RRP9 affects processing of other RNA species could reveal new functions

• Potential Roles in Development:

  • Given its fundamental role in ribosome biogenesis, RRP9 may have important developmental functions

  • Studies in model organisms could reveal developmental processes requiring RRP9

• Stress Response Mechanisms:

  • Investigation into how RRP9 may participate in cellular stress responses through modulation of protein synthesis

  • Stress conditions may alter RRP9 function or localization

How do post-translational modifications affect RRP9 function and interactions?

Post-translational modifications (PTMs) of RRP9 appear to be critical regulators of its function:

• Neddylation:

  • RRP9 undergoes neddylation, which attaches the ubiquitin-like protein Nedd8 to specific lysine residues

  • The E3 ubiquitin ligase Smurf1 interacts specifically with the WD40 domain (aa 145-475) of RRP9

  • This interaction suggests Smurf1 may regulate RRP9 through neddylation

• Potential Phosphorylation:

  • As RRP9 activates the AKT signaling pathway , it may itself be regulated by phosphorylation

  • Investigation of potential phosphorylation sites and their functional significance could reveal regulatory mechanisms

• Ubiquitination:

  • While RRP9 affects the ubiquitination of other proteins like JUN , its own ubiquitination status and turnover remain areas for investigation

  • Understanding RRP9 protein stability and degradation pathways could provide therapeutic opportunities

• PTM Crosstalk:

  • Potential interactions between different PTMs (neddylation, phosphorylation, ubiquitination) in regulating RRP9

  • How these modifications collectively determine RRP9's function, localization, and interactions

• Context-Dependent Modifications:

  • How different cellular contexts (normal vs. cancer, different tissue types) affect the PTM profile of RRP9

  • Techniques such as mass spectrometry could map comprehensive PTM profiles in different conditions

What experimental approaches can resolve contradictory findings about RRP9's mechanism of action?

To address contradictory findings about RRP9's mechanism of action, researchers can employ several approaches:

• Cell Type-Specific Analysis:

  • Systematically compare RRP9 function across multiple cell lines and primary cells

  • Determine whether contradictions arise from cell type-specific effects

  • For example, compare mechanisms in breast cancer vs. pancreatic cancer models

• Comprehensive Interactome Analysis:

  • Perform unbiased proteomics to identify all RRP9 interacting partners

  • BioID or proximity labeling approaches can identify transient or weak interactions

  • Compare interactomes across different cellular contexts to identify context-specific interactions

• Domain-Specific Function Analysis:

  • Create a panel of RRP9 mutants with alterations in specific functional domains

  • Determine which functions are affected by each mutation

  • This can help separate direct vs. indirect effects and resolve contradictory findings

• Temporal Resolution Studies:

  • Employ time-course experiments with high temporal resolution

  • Determine the sequence of events following RRP9 manipulation

  • This can help distinguish primary from secondary effects

• Systems Biology Approaches:

  • Integrate multiple omics datasets (transcriptomics, proteomics, metabolomics)

  • Build comprehensive network models of RRP9 function

  • Computational modeling can predict and reconcile apparently contradictory observations

• In Vivo Validation:

  • Test competing hypotheses in appropriate animal models

  • Tissue-specific or inducible knockout/knockdown models can resolve context-dependent functions

  • Patient-derived xenografts can better recapitulate human disease complexity

By employing these approaches, researchers can develop a more nuanced understanding of RRP9's functions and resolve apparent contradictions in the literature.